<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168171">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917799</url>
  </required_header>
  <id_info>
    <org_study_id>LDA and LMWH</org_study_id>
    <nct_id>NCT01917799</nct_id>
  </id_info>
  <brief_title>Aspirin, Heparin and Miscarriage</brief_title>
  <official_title>Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Khartoum</source>
  <oversight_info>
    <authority>Libya:Misurata Central Hospital</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of low dose aspirin (LDA) versus LDA plus low-molecular-weight-heparin (LMWH) in
      patients with a history of recurrent miscarriages.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of miscarriages</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To  compare number of miscarriages between  the two  groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pregnancy</condition>
  <condition>Miscarriage</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg tab of aspirin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin  + heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>75mg tab of LDA once daily for 7 months</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Aspirin  + heparin</arm_group_label>
    <other_name>LDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>0.4 mL/day of the Enoxaparin</description>
    <arm_group_label>Aspirin  + heparin</arm_group_label>
    <other_name>Enoxaparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women

          -  History of 2 or more of miscarriage

        Exclusion Criteria:

          -  Twins
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Misurata Teaching Hospital</name>
      <address>
        <city>Misurata</city>
        <zip>218</zip>
        <country>Libyan Arab Jamahiriya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed O Elmahashi, MD</last_name>
      <phone>+249911259199</phone>
      <phone_ext>-</phone_ext>
      <email>essadifathi@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bashir M Ashur, MD</last_name>
      <phone>+249911259199</phone>
      <phone_ext>-</phone_ext>
      <email>bmashur@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Libyan Arab Jamahiriya</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Khartoum</investigator_affiliation>
    <investigator_full_name>Ishag Adam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Heparin</keyword>
  <keyword>pregnancy</keyword>
  <keyword>miscarriage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
